David Komander

The paper investigates ZnF-UBP domains in USP DUBs, showing they relieve product inhibition by facilitating Ub release, thereby regulating enzyme activity.

This study develops refined USP25/28 inhibitors that selectively target c-MYC driven squamous lung cancer cells with reduced off-target effects and toxicity.

This study identifies WEHI-092, a USP9X inhibitor, and shows it arrests cancer cells in metaphase, suggesting USP9X inhibitors could be selective mitotic poisons.

This study identifies glucose-limiting conditions and a GID/CTLH-type E3 ubiquitin ligase as key factors in Toxoplasma differentiation into latent forms.

This study demonstrates that HOIL-1 can ubiquitinate non-proteinaceous substrates like saccharides in vitro, identifies a key residue for this activity, and produces ubiquitinated saccharides as potential tools.

The paper uses Deep Mutational Scanning to analyze SARS-CoV-2 PLpro mutations, identifying functional residues and drug-escape variants.

This study identifies PPTC7 as a cofactor for SCFFBXL4-mediated degradation of BNIP3 and NIX, suppressing mitophagy and revealing a feedback mechanism to regulate mitochondrial homeostasis.

The paper investigates PINK1's interaction with nucleotides and kinetin, revealing structural changes and binding constraints that affect its activity and mitophagy.

This study demonstrates that MLKL ubiquitylation, triggered by oligomerization, regulates necroptosis by modulating MLKL activity and turnover.

The paper shows that an 'invisible' conformation of ubiquitin enhances its phosphorylation by PINK1 through a dynamic equilibrium involving the Ser65 loop.